Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a partnership with Sino-Canadian firm Geneseeq Technology Inc. The collaboration aims to jointly develop and commercialize a companion diagnostic (CDx) reagent for Vcare’s NTRK inhibitor VC004. Financial details of the agreement were not disclosed.
Preliminary clinical data indicate that VC004, a second-generation NTRK inhibitor developed in-house by Vcare Pharma, exhibits excellent in vitro and in vivo activity, favorable pharmacokinetic properties, good tolerability, and a high response rate. The product, currently in Phase II development, targets solid tumors. There is no similar product approved for marketing in China at present.
Geneseeq, a leading company in tumor precision testing in China, is the only firm with two next-generation sequence (NGS) medical device reagent products in the country. Vcare Pharma, on the other hand, specializes in innovative drugs and cutting-edge therapies, with a focus on indications in oncology, cardiovascular and cerebrovascular diseases, and autoimmune diseases.- Flcube.com
